BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 166-172

  Moon, Joon Ho ^a   Sohn, Sang Kyun ^a   Lee, Myung Hoon ^a   Jang, Jun Ho ^b   Kim, Kihyun ^b   Jung, Chul Won ^b   Kim, Dong Hwan ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; Bcl 2; Single nucleotide polymorphism

Indexed keywords

ADENOSINE; CYTARABINE; CYTOSINE; GUANOSINE; IDARUBICIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CYTOGENETICS; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENES, BCL-2; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74849120847     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.009     Document Type: Article

References (28)

1. Klampfer L., Zhang J., Zelenetz A.O., Uchida H., and Nimer S.D. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 93 (1996) 14059-14064
2. Rassool F.V., Gaymes T.J., Omidvar N., Brady N., Beurlet S., Pla M., et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?. Cancer Res 67 (2007) 8762-8771
3. Peters R., Leyvraz S., and Perey L. Apoptotic regulation in primitive hematopoietic precursors. Blood 92 (1998) 2041-2052
4. Delia D., Aiello A., Soligo D., Fontanella E., Melani C., Pezzella F., et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79 (1992) 1291-1298
5. Bensi L., Longo R., Vecchi A., Messora C., Garagnani L., Bernardi S., et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 80 (1995) 98-102
6. Karakas T., Maurer U., Weidmann E., Miething C.C., Hoelzer D., and Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 9 (1998) 159-165
7. Casas S., Ollila J., Aventin A., Vihinen M., Sierra J., and Knuutila S. Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet 146 (2003) 89-101
8. Andreeff M., Jiang S., Zhang X., Konopleva M., Estrov Z., Snell V.E., et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13 (1999) 1881-1892
9. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 11 (1997) 2075-2078
10. Nuckel H., Frey U.H., Bau M., Sellmann L., Stanelle J., Durig J., et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 109 (2007) 290-297
11. Sohn S.K., Kim D.H., Kim J.G., Lee N.Y., Suh J.S., Lee K.S., et al. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant 34 (2004) 63-68
12. Sohn S.K., Kim J.G., Sung W.J., Kim D.H., Suh J.S., Lee K.S., et al. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. J Clin Apheresis 18 (2003) 186-189
13. Sohn S.K., Kim J.G., Chae Y.S., Kim D.H., Lee N.Y., Suh J.S., et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 18 (2003) 10-15
14. Tanaka S., Kant J., and Reed J.C. G to A polymorphism in the second exon of the BCL2 gene. Nucleic Acids Res 19 (1991) 1964
15. In: Mitelman F. (Ed). ISCN 1995: an international system for human cytogenetic, nomenclature 1995 (1995), S. Karger, Basel, Switzerland
16. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
17. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151-157
18. Kondo S., Yin D., Morimura T., Oda Y., Kikuchi H., and Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res 54 (1994) 2928-2933
19. Guedez L., Suresh A., Tung F., and Zucali J. Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Eur J Haematol 57 (1996) 149-156
20. Keith F.J., Bradbury D.A., Zhu Y.M., and Russell N.H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 9 (1995) 131-138
21. Maung Z.T., MacLean F.R., Reid M.M., Pearson A.D., Proctor S.J., Hamilton P.J., et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 88 (1994) 105-109
22. Kornblau S.M., Thall P.F., Estrov Z., Walterscheid M., Patel S., Theriault A., et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5 (1999) 1758-1766
23. Karakas T., Miething C.C., Maurer U., Weidmann E., Ackermann H., Hoelzer D., et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 16 (2002) 846-854
24. Seto M., Jaeger U., Hockett R.D., Graninger W., Bennett S., Goldman P., et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7 (1988) 123-131
25. Young R.L., and Korsmeyer S.J. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 13 (1993) 3686-3697
26. Park B.L., Kim L.H., Cheong H.S., Cho H.Y., Kim E.M., Shin H.D., et al. Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2). J Hum Genet 49 (2004) 449-454
27. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21 (2005) 263-265
28. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 68 (2001) 978-989